聚乙二醇干扰素α短期治疗HBsAg水平极低的非活动性HBsAg携带者的疗效观察  

The efficacy of short-term treatment with Peg-interferonαfor inactive hepatitis B surface antigen carriers with extremely low HBsAg levels

作　　者：赵海东 陈灵峰 林巧欣 李艺芳 ZHAO Hai-dong;CHEN Ling-feng;LIN Qiao-xin;LI Yi-fang(Department of Infectious Disease,Xiamen Chang Gung Hospital,Xiamen 361029,China;Department of Laboratory,Xiamen Chang Gung Hospital,Xiamen 361029,China)

机构地区：[1]厦门长庚医院感染科,361029 [2]厦门长庚医院检验科,361029

出　　处：《肝脏》2020年第9期937-939,共3页Chinese Hepatology

摘　　要：目的观察HBsAg水平极低的非活动性HBsAg携带者(Inactive hepatitis B surface antigen carriers,IHC经短期聚乙二醇干扰素α-2b(Peg IFNα-2b)治疗后的HBsAg清除率。方法自2017年4月至2018年12月,共38例IHC就诊于厦门长庚医院,既往未进行抗病毒治疗,且HBsAg水平均小于15 IU/mL。根据患者治疗意愿分为Peg IFNα治疗组(12例)或对照组(26例)。治疗组皮下注射Peg IFNα-2b180μg/周,疗程为24周。对照组未给予抗病毒治疗,中位随访55.7(25.3,79.2)周。运用卡方检验比较两组HBsAg的清除率和血清学转换率的差异,运用logistic回归分析基线特征、Peg IFNα-2b治疗与HBsAg清除间的相关性。结果 24周时,PegIFNα治疗组中83.3%(10/12)IHC获得HBsAg清除,41.6%(5/12)获得HBsAg血清学转换,对照组中有7.7%(2/26)IHC获得HBsAg清除,无一例发生HBsAg血清学转换,Peg IFNα治疗组的HBsAg清除率和HBsAg血清学转换率显著高于对照组(P<0.05)。Peg IFNα-2b治疗可增加IHC的HBsAg清除率(OR=60.00,95%CI:7.39~487.14)。结论 Peg IFNα-2b短期治疗HBsAg水平极低的IHC可以提高HBsAg清除率和HBsAg血清学转换率。Objective HBsAg loss represents clinical cure of hepatitis B.The aim of the present study was to investigate the HBsAg loss rate in inactive hepatitis B surface antigen carriers(IHCs)with extremely low HBsAg levels after peg-interferonα-2 b(Peg-IFNα)short-term treatment.Methods Thirty-eight cases of IHCs were included in this study.They were treatment-nave and the average baseline HBsAg level were less than 15 IU/mL.According to the patients’willingness,they were divided into Peg-IFNαtreatment group(N=12 cases)or control group(N=26 cases).The Peg-IFNαtreatment group was subcutaneously injected with180μg/week of Peg-IFNα-2 b for 24 weeks.The control group were followed up without treatment for a median of 55.7(25.3±79.2)weeks.SPSS25.0 software was used for statistical analysis.,Chi-square test was used to compare the difference in HBsAg loss rate and HBsAg seroconversion rate between the two groups.Logistic regression was used to analyze the correlation between baseline characteristics,Peg-IFNαtreatment and HBsAg loss.Results At 24 weeks,83.3%(N=10)IHCs in the Peg-IFNαtreatment group achieved HBsAg loss and 41.6%(N=5)IHCs achieved HBsAg seroconversion.7.7%(N=2)IHCs in the control group had HBsAg loss and HBsAg seroconversion rate was 0.The HBsAg loss rate and HBsAg seroconversion rate in Peg-IFNαtreatment group were statistically higher than that of the control group(P<0.05).By univariate analysis it was found that Peg-IFNαtreatment significantly increased HBsAg clearance of IHCs(OR=60.00,95%CI:7.39-487.14).Conclusion Peg-IFNαshort-term treatment for IHCs with extremely low HBsAg levels may significantly improve HBsAg loss rate and HBsAg seroconversion rate.

关 键 词：非活动性HBSAG携带者 聚乙二醇干扰素Α 慢性乙型肝炎 HBsAg水平极低 HBsAg清除 临床治愈 

分 类 号：R512.62[医药卫生—内科学]